Announcements

Australian cancer treatment development company Prima BioMed Ltd (“Prima”) (ASX: PRR) is pleased to announce that it has received Notification of Grant by the Japanese Patent Office for its antibody to cancer antigen Cripto-1.

Patent number 4854912 is titled, Antibodies against Cancer and expires in March 2022.The patent has also been granted in Australia, New Zealand, China, South Korea and the USA.